Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer

BACKGROUND: Variant ATM heterozygotes have an increased risk of developing cancer, cardiovascular diseases, and diabetes. Costs and time of sequencing and ATM variant complexity make large-scale, general population screenings not cost-effective yet. Recently, we developed a straightforward, rapid, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Prodosmo, Andrea, Buffone, Amelia, Mattioni, Manlio, Barnabei, Agnese, Persichetti, Agnese, De Leo, Aurora, Appetecchia, Marialuisa, Nicolussi, Arianna, Coppa, Anna, Sciacchitano, Salvatore, Giordano, Carolina, Pinnarò, Paola, Sanguineti, Giuseppe, Strigari, Lidia, Alessandrini, Gabriele, Facciolo, Francesco, Cosimelli, Maurizio, Grazi, Gian Luca, Corrado, Giacomo, Vizza, Enrico, Giannini, Giuseppe, Soddu, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012020/
https://www.ncbi.nlm.nih.gov/pubmed/27599564
http://dx.doi.org/10.1186/s13046-016-0410-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012020/
https://www.ncbi.nlm.nih.gov/pubmed/27599564
http://dx.doi.org/10.1186/s13046-016-0410-3

Ejemplares similares